/eh/2025-01-08/173633966714069467/picture.png)
/eh/2024-12-24/173503345348979036/Favorite-Icon.png){kind=icon}
/eh/2025-07-08/1751962110204480194/picture.png)
/eh/2025-06-21/1750485478958537574/countryInfoIcon.png)
/eh/2025-06-21/1750485741321434291/Hi-Sign-in-My-Nihao.png)
/eh/2025-06-21/1750485837193896318/cart.png)
/eh/2025-06-21/1750485968202533847/cart.png)
/eh/2025-04-17/1744862476612819675/hot-img.png)
/eh/2025-11-07/1762504524550532584/header-icon.jpg){kind=icon}
/eh/2025-07-07/1751875582852206790/header-icon.png){kind=icon}
/eh/2025-07-07/1751875587886277738/header-icon.png){kind=icon}
home
>
glutathione and triple negative breast cancer RK-251 is a ROS-responsive fluorogenic prodrug developed by researchers at IIT Guwahati IASST. It is designed to release NBDHEX, an inhibitor of S-transferase pi (GSTP1), when activated by reactive oxygen hide_varints
>
glutathione and triple negative breast cancer RK-251 is a ROS-responsive fluorogenic prodrug developed by researchers at IIT Guwahati IASST. It is designed to release NBDHEX, an inhibitor of S-transferase pi (GSTP1), when activated by reactive oxygen hide_varints
download picture
description
glutathione and triple negative breast cancer RK-251 is a ROS-responsive fluorogenic prodrug developed by researchers at IIT Guwahati IASST. It is designed to release NBDHEX, an inhibitor of S-transferase pi (GSTP1), when activated by reactive oxygen hide_varints
Shopping security
product description
Why choose thelockerguy wholesale?
glutathione and triple negative breast cancer RK-251 is a ROS-responsive fluorogenic prodrug developed by researchers at IIT Guwahati IASST. It is designed to release NBDHEX, an inhibitor of S-transferase pi (GSTP1), when activated by reactive oxygen hide_varints
Buy FOXO4-DRI Peptide for Research | 99%+ Purity | PHP
doi: 10.1007/s12070-023-04217-y 96
hide_varints
Menge:9 STÜCK
As research continues to unfold, these prospects have the potential to reshape health paradigms, rejuvenate industries, and contribute to a more sustainable and health-conscious global future [4, 140]
glutathione and triple negative breast cancer RK-251 is a ROS-responsive fluorogenic prodrug developed by researchers at IIT Guwahati IASST. It is designed to release NBDHEX, an inhibitor of S-transferase pi (GSTP1), when activated by reactive oxygen hide_varints
Item no
:
71829234401
US$ 29.01
Pay in 4 interest-free payments of $7.25 Learn more
Min. order:
1piece
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
US$40
Get nowSign up to your membership to get coupons up to
15%
Get nowOpportunity to enjoy order discount up to 15% off
Please add the products
Shipping Notes
- Free Standard Shipping on $100+ Orders to the USA.
- Except Preorder products are shipped in 48 hours.
- Delivery to the USA:
- Standard Shipping : 3-10 business days
- If time is of the essence, please consider selecting expedited delivery for faster service.
Exchange/Return Notes
- We offer a 30-day return/exchange service after receiving.
- Final sale items are not eligible for returns or exchanges.
- To process your return/exchange, please contact us at [email protected]
- Please click here for more details>>> Return & Exchange Policy
Frequently Asked Questions for glutathione and triple negative breast cancer RK-251 is a ROS-responsive fluorogenic prodrug developed by researchers at IIT Guwahati IASST. It is designed to release NBDHEX, an inhibitor of S-transferase pi (GSTP1), when activated by reactive oxygen hide_varints
What should I confirm before asking a seller to hold an order?
Clarify which action you want temporarily paused and why. Use the existing order reference when making the request.
How should I use an automated answer from a seller's help system?
Do not treat suggested steps as proof they have been completed. Avoid sharing passwords or verification codes in the help conversation.
How can I find out whether a special request can be accommodated?
Distinguish an essential requirement from a preference you could do without. Confirm any new requirements that would apply to the modified offer.